EPIC Health Systems home
Reach Us
Pharmaceutical & supply chain

Costs and outcomes of antimicrobial stewardship for children

A pilot stewardship programme in two primary hospitals in Gondar Zone improved prescribing for hospitalised children, but its costs and value have not been assessed. This project estimates the economic burden of antimicrobial resistance in these hospitals and the cost-effectiveness of the programme.

CountryEthiopia
PeriodFebruary 2026 – January 2027
StatusOngoing
Health topicAntimicrobial resistance, Child health
01

Challenge

Drug-resistant bloodstream infections account for a large share of hospital deaths among children in Ethiopia. Stewardship programmes are being piloted in primary hospitals, and decision makers need evidence on whether they are worth expanding.

02

Approach

A cost-of-illness model separates direct costs, such as antimicrobials, blood cultures and bed-days, from indirect costs such as caregiver time and out-of-pocket spending. A Markov cohort model compares the stewardship programme with standard care over a lifetime horizon, with QALYs as the main outcome. The analysis also looks at how costs and benefits fall across households.

03

Progress

The modelling protocol is complete and is with the ethics committee. Stewardship teams at Metema and Debark primary hospitals have agreed to share clinical, microbiology, pharmacy and audit data once approval is in place. The Ministry of Health and the regional health bureau have been briefed ahead of a model validation workshop.

04

Expected outputs

Estimates of the cost of resistance among children in hospital, the cost-effectiveness of stewardship in primary hospitals, and evidence for national scale-up.

Work with us.

We take enquiries from governments, development partners, research institutions and implementers on research, advisory and training engagements.

Get in touch
Partners & collaborators

Who we work with